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Objectives We sought to test the prognostic performance of thrombus precursor protein (TpP) in patients presenting with an
acute coronary syndrome (ACS).
Background Because thrombus formation is a critical step in the development of ACS, a measurement of activated coagula-
tion could yield important information. Thrombus precursor protein is a biomarker that is used to measure solu-
ble fibrin polymers, which are the penultimate products in fibrin formation.
Methods We measured the levels of TpP in 284 healthy volunteers and in 2,349 patients with ACS.
Results Median TpP concentrations were 3.6 g/ml (interquartile range 2.6 to 5.5) in the volunteers and 8.9 g/ml
(interquartile range 4.9 to 15.9) in the ACS patients (p  0.001). Patients with ACS who had elevated TpP were
older, more likely to be women, and more likely to have diabetes and pre-existing CAD (p  0.02 for each).
Thrombus precursor protein levels greater than the median were associated with a significantly increased risk
for the composite of death, myocardial infarction (MI), or recurrent ischemia leading to rehospitalization or ur-
gent revascularization through 10 months (hazard ratio [HR] 1.45, p  0.001), as well as death or MI (HR 1.42,
p  0.02). We found that TpP correlated only weakly with cardiac troponin I, B-type natriuretic peptide, and high-
sensitivity C-reactive protein (|r| 0.15 for each). After adjusting for clinical characteristics, cardiac troponin I,
high-sensitivity C-reactive protein, and B-type natriuretic peptide, we found that patients with TpP levels greater
than the median remained at significantly increased risk for the composite outcome (adjusted HR 1.51, p 
0.001) and death or MI (adjusted HR 1.58, p  0.02).
Conclusions In patients with ACS, increased levels of TpP are associated with an increased risk of death or ischemic compli-
cations. The incorporation of a marker of activated coagulation, such as TpP, with established cardiovascular
risk factors may offer valuable complementary insight into risk assessment in ACS. (J Am Coll Cardiol 2008;
51:2422–9) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.01.069fl
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June 24, 2008:2422–9 TpP and Clinical Outcomes in ACSave not been widely adopted in this setting (3). However,
ecause thrombus formation is usually a critical step in the
evelopment of an ACS, an effective measurement of the
nd products of coagulation could yield important prog-
ostic information.
To that end, a marker of interest that is closely related to
he formation of fibrin is thrombus precursor protein (TpP),
specific form of soluble fibrin (3). After thrombin cleaves
brinopeptide A and B from fibrinogen, desAABB fibrin
onomers are formed. These monomers polymerize into
oluble TpP fibrin polymers, which serve as the immediate
recursors to insoluble fibrin (Fig. 1) (4,5). We examined
pP levels in healthy volunteers and then investigated the
rognostic performance of TpP in a large cohort of patients
resenting with ACS. We also assessed the incremental
nformation provided by TpP after adjustment for tradi-
ional clinical risk factors, presenting features, and estab-
ished biomarkers.
ethods
tudy population. The present analysis was conducted on
,349 patients with ST-segment elevation myocardial in-
arction (STEMI), non–ST-segment elevation myocardial
nfarction (NSTEMI), and patients with unstable angina
UA) who were enrolled in the OPUS–TIMI 16 (Oral
lycoprotein IIb/IIIa Inhibition With Orbofiban in Pa-
ients With Unstable Coronary Syndromes–Thrombolysis
n Myocardial Infarction 16) trial. The design and primary
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Figure 1 Fibrin Formation
Formation of fibrin and identification of thrombus precursor protein (TpP). D  D-desults of the study have been
escribed (6). The TpP study
ncluded subjects who were
reated with 50 mg of orbofiban
wice daily and had blood sam-
les available for analysis. Pa-
ients were followed up through
0 months and evaluated for car-
iovascular events. Clinical out-
omes for this analysis included
eath, myocardial infarction (MI),
ecurrent ischemia leading to re-
ospitalization, and recurrent isch-
mia leading to urgent revascu-
arization, as well as the composite
f these 4 end points. A blinded
linical Events Committee adju-
icated all suspected cases of MI
nd recurrent ischemia. The pro-
ocol, including the biomarker
ubstudy, was reviewed and ap-
roved by the institutional review
oard/ethics committees at each participating institution, and
ll patients provided written informed consent.
iomarker testing. To approximate the normal range for
pP, citrate plasma samples were collected from 284
ealthy volunteers (mean age 34 years, 50% male). Citrate
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TpP and Clinical Outcomes in ACS June 24, 2008:2422–9he time of enrollment, which was a median of 40 h (5th
ercentile: 8 h, 95th percentile: 71 h) from presentation.
amples were frozen and sent to the TIMI Biomarker
aboratory (Boston, Massachusetts), where they were
tored at 70°C. Samples were subsequently analyzed at
iosite, Inc. (San Diego, California), where sequential
andwich immunoassays were used to measure TpP (n 
,349), cardiac troponin I (TnI) (n  2,320), B-type
atriuretic peptide (BNP) (n  2,324), and high-sensitivity
-reactive protein (hsCRP) (n  1,929) with an automated
ystem (Tecan Genesis robotic sample processor 200/8,
urham, North Carolina).
We measured TpP using an antifibrin MH1 monoclonal
ntibody that binds to specific neoepitopes of soluble
rosslinked and noncross-linked desAABB fibrin polymers
7). The assay system is designed to exclude detection of
brinogen, fibrinogen-degradation products, desAA fibrin
onomers, desAA fibrin polymers, desAABB fibrin mono-
ers, crosslinked fibrinogen, desAA fibrin monomer-
brinogen complexes, fibrin degradation products, and
rosslinked fibrin degradation products. The TpP assay has
minimal detectable concentration of 0.27 g/ml and a
otal imprecision of 13% and 8% at concentrations of 1
g/ml and 20 g/ml, respectively, in healthy volunteers.
he stability of TpP during long-term storage was assessed
y comparing TpP concentrations across different durations
f storage in the study population; there was no difference
ver time (p  0.79).
The minimal detectable concentration of the TnI assay
as 0.05 ng/ml. Decision limits of 1.5 and 0.1 ng/ml were
sed for the TnI analyses (8). Analyses that included BNP
ere performed with the use of a threshold of 80 pg/ml
8,9). For hsCRP, a threshold of 15 mg/l was used in the
etting of ACS (10).
tatistical analysis. All patients with available data for
pP were included in this analysis. The plasma levels of
pP were described by the median and interquartile range
n the healthy volunteers and study population. In OPUS–
IMI 16, baseline characteristics of patients in the 4 TpP
uartiles were compared using the Kruskal-Wallis test for
rend for continuous variables and the chi-square test for
rend for categorical variables. Correlations between TpP
evels and other biomarkers, as well as duration of treatment
ith heparin, were examined using Spearman correlation
oefficients. Because of nonlinearity, we analyzed TpP by
sing quartiles and as a dichotomous variable divided at the
edian. Cumulative incidence curves were plotted with the
elson-Aalen method (11,12). When performing stratified
nalyses, ST-segment elevation ACS and non–ST-segment
levation ACS events (UA and NSTEMI) were assessed
ased on the approach used in the American College of
ardiology/American Heart Association management
uidelines (13). Multivariable analyses of the association
etween TpP and outcomes were performed with a Cox
roportional hazards survival model to adjust for traditional
ardiovascular risk factors (age, gender, hypertension, smok- ang status, diabetes, body mass index, dyslipidemia, pre-
xisting coronary disease, and prior aspirin use), clinical
eatures on presentation (index diagnosis, creatinine clear-
nce, Killip class, use of heparin, and use of beta-blockade),
nd other biomarkers (TnI, CRP, and BNP). Statistical
eterogeneity was assessed with interaction terms within a
ox proportional hazards survival model. All analyses were
erformed with Stata/SE 9.2 (STATA Corporation, Col-
ege Station, Texas). Two-sided p values 0.05 were
onsidered to indicate statistical significance.
esults
pP levels. In a population of 284 healthy volunteers, the
edian TpP value was 3.7 g/ml, with the 5th, 25th, 75th,
nd 95th percentiles at 1.6, 2.6, 5.6, and 8.9 g/ml,
espectively. In the OPUS–TIMI 16 study population, the
edian concentration of TpP was 8.9 g/ml, with the 5th,
5th, 75th, and 95th percentiles at 1.4, 4.9, 15.9, and 68.1
g/ml, respectively (p  0.001 compared with the healthy
opulation).
aseline clinical characteristics and presentation. The
linical characteristics of patients in the study population,
tratified by TpP quartiles, are presented in Table 1.
atients with TpP levels in the upper quartiles were mod-
stly older and more likely to be female and have a greater
ody mass index, history of diabetes, pre-existing coronary
rtery disease, and prior use of aspirin (p  0.02 for each).
here were trends toward greater levels of TpP among
atients with hypertension and with dyslipidemia.
Patients with greater TpP levels had modestly lower
alculated creatinine clearances and more commonly dis-
layed evidence of heart failure on examination (Killip class
I to IV) (Table 2). Patients with TpP levels in the upper
uartiles were more likely to have UA than STEMI; the
edian TpP levels were 9.7 g/ml in patients with UA, 8.5
g/ml in NSTEMI, and 7.9 g/ml in STEMI (p 0.001).
here was no significant difference in time from symptom
nset to randomization across the TpP quartiles. Similarly,
edian TpP levels did not differ based on time from
ymptom onset to randomization (0 to 24 h: 9 g/ml, 24 to
8 h: 8.5 g/ml, 48 h: 9.2 g/ml, p  0.58). Morever,
here was no significant correlation between TpP concen-
rations and time from symptom onset to randomization
r  0.02, p  0.28).
Patients in all 4 TpP quartiles underwent percutaneous
oronary revascularization at similar rates. Whereas the
dministration of aspirin, angiotensin-converting enzyme
nhibitors, and calcium channel blockers did not vary by
pP quartile, patients in the upper quartiles of TpP were
ess likely than patients in the lower quartiles to be treated
ith beta-blockers. The use of heparin in patients varied
cross TpP quartiles, with patients in the top quartiles less
ikely to have received unfractionated heparin. Similarly, the
edian TpP levels among patients treated with unfraction-
ted heparin, low molecular weight heparin, or no heparin
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June 24, 2008:2422–9 TpP and Clinical Outcomes in ACSiffered (8.2, 10.6, and 10.1 g/ml, respectively, p 0.001).
f note, patients with UA were less likely than patients who
xperienced an MI to be treated with unfractionated hepa-
in at the time of the TpP collection (55.3% vs. 67.0%, p 
.001). Notably, among patients on unfractionated heparin
ith partial thromboplastin time (PTT) values obtained
ithin 6 h of the TpP sample acquisition, the correlation
etween the TpP and PTT levels was weak (r  0.10, p
0.20). Likewise, there was only a modest correlation
etween TpP levels and the duration of treatment with
pP and Baseline Clinical Characteristics
Table 1 TpP and Baseline Clinical Characteristics
TpP Q
<4.9 (n  596) 4.9–8.9 (n  590)
Age, yrs 59.3  11.6 60.4  11.5
Male gender 458 (76.9) 413 (70.0)
Hypertension 222 (37.3) 255 (43.3)
Smoking
Current 231 (38.8) 224 (38.0)
Past 175 (29.4) 193 (32.8)
Never 190 (31.9) 172 (29.2)
Diabetes 105 (17.6) 131 (22.2)
BMI, kg/m2 27.6  4.7 28.7  15.0
Dyslipidemia 148 (24.9) 175 (29.7)
Previous CAD 242 (40.6) 290 (49.2)
Previous aspirin 198 (33.3) 232 (39.4)
ata are shown as n (%) or mean  SD. *Global p value.
BMI  body mass index; CAD  coronary artery disease; TpP  thrombus precursor protein.
pP and Presentation and Treatment Characteristics
Table 2 TpP and Presentation and Treatment Characteristics
T
<4.9 (n  596) 4.9–8.9 (n 
Data on presentation
Systolic BP, mm Hg 127.2  20.5 129.2  20
Heart rate, beats/min 72.0  13.7 73.1  13
Creatinine clearance, ml/min 106.5  39.5 107.6  43
Chest pain to randomization, h 39.2  18.9 41.0  19
Killip class II to IV 44 (7.5) 48 (8.3)
ST-segment deviation 1 mm 294 (49.3) 265 (44.9
Index diagnosis
UA 197 (33.1) 282 (47.8
NSTEMI 138 (23.2) 142 (24.1
STEMI 260 (43.7) 166 (28.1
Treatment
PCI 119 (20.0) 96 (16.3
Heparin
UFH 420 (70.5) 377 (64.0
LMWH 66 (11.1) 65 (11.0
None 110 (18.5) 147 (25.0
Aspirin 586 (98.3) 584 (99.0
ACE inhibitors 234 (39.3) 235 (39.8
Beta-blockers 436 (73.2) 427 (72.4
Calcium-channel blockers 111 (18.6) 131 (22.2
ata are shown as n (%) or mean  SD. *Global p value.
BP  blood pressure; LMWH  low-molecular-weight heparin; NSTEMI  non–ST-segment elevation m
yocardial infarction; TpP  thrombus precursor protein; UA  unstable angina; UFH  unfractionated hnfractionated heparin before the TpP levels were drawn (r
0.07, p  0.01).
linical outcomes. There was a significant association
etween greater levels of TpP and risk for the composite
utcome of death, MI, recurrent ischemia leading to rehos-
italization, or recurrent ischemia leading to urgent revas-
ularization (p  0.0003) (Table 3). We observed direc-
ional consistency for all of the individual components of the
omposite outcome (Table 3). Patients in the top 2 quartiles
ere at comparably increased risk compared with the
s (g/ml)
9–15.9 (n  577) >15.9 (n  586) p Value for Trend
61.4  11.4 61.5  11.6 0.001
412 (71.4) 405 (69.1) 0.008
253 (43.9) 252 (43.0) 0.051
200 (34.7) 196 (33.6) 0.092*
204 (35.4) 181 (31.1)
172 (29.9) 206 (35.3)
125 (21.7) 140 (23.9) 0.015
28.3  4.9 28.9  12.6 0.002
159 (27.6) 181 (31.0) 0.051
306 (53.0) 328 (56.0) 0.001
248 (43.0) 267 (45.6) 0.001
artiles (g/ml)
9–15.9 (n  577) >15.9 (n  586) p Value for Trend
129.8  21.5 129.0  21.0 0.126
72.2  14.6 73.2  14.2 0.415
102.6  40.9 101.0  38.8 0.005
42.5  20.3 40.4  20.3 0.207
49 (8.6) 65 (11.2) 0.029
268 (46.5) 270 (46.1) 0.367
0.001*
271 (47.0) 305 (52.1)
136 (23.6) 114 (19.5)
170 (29.5) 167 (28.5)
97 (16.8) 95 (16.2) 0.122
344 (59.6) 307 (52.6) 0.001*
90 (15.6) 93 (15.9)
143 (24.8) 184 (31.5)
569 (98.6) 574 (98.0) 0.517
236 (40.9) 246 (42.0) 0.308
397 (68.8) 401 (68.4) 0.034
116 (20.1) 101 (17.2) 0.396uartilepP Qu
590)
.3
.7
.0
.7
)
)
)
)
)
)
)
)
)
)
)
)yocardial infarction; PCI  percutaneous coronary intervention; STEMI  ST-segment elevation
eparin.
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TpP and Clinical Outcomes in ACS June 24, 2008:2422–9ottom 2 quartiles and, therefore, the study population was
urther assessed using median values. Patients with TpP
evels greater than the median (8.9 g/ml) were at a
.45-fold increased risk of the composite end point (95%
onfidence interval [CI] 1.20 to 1.75, p  0.001) (Fig. 2),
nd were also at increased risk of death or MI (hazard ratio
HR] 1.42, 95% CI 1.05 to 1.93, p  0.02) (Fig. 3).
Increased TpP levels remained associated with an in-
reased risk of death or ischemic complications regardless of
ndex ACS diagnosis (STEMI: HR 1.66, 95% CI 1.18 to
.34 and NSTEMI/UA: HR 1.35, 95% CI 1.07 to 1.70)
Fig. 4). Levels of TpP greater than the median were also
ssociated with an increased risk of the composite outcome
n patients with and without pre-existing coronary artery
isease. Furthermore, there was no heterogeneity in the
rognostic utility of TpP in subjects stratified by time from
schemic symptoms to randomization or type of antithrom-
otic therapy used.
ultivariable analysis. After adjusting for baseline char-
cteristics and clinical features on presentation (including
ge, gender, smoking status, hypertension, dyslipidemia,
ody mass index, diabetes, pre-existing coronary disease,
rior aspirin use, index diagnosis, creatinine clearance,
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Figure 2 Cumulative Incidence of the
Composite Outcome by TpP Level
Cumulative incidence of the composite outcome (death, myocardial infarction,
ischemia requiring revascularization, or ischemia requiring rehospitalization)
through 10 months stratified by TpP levels  median (8.9 g/ml) or 
median. CI  confidence interval; HR  hazard ratio; TpP  thrombus precur-
sor protein.
ssociation Between TpP and Clinical Events Through 10 Months
Table 3 Association Between TpP and Clinical Events Through
Clinical Outcomes <4.9 (n  596) 4.
Composite outcome (n  434) 17.5
Death (n  77) 3.5
Myocardial infarction (n  113) 4.9
Ischemia requiring urgent revascularization (n  137) 4.9
Ischemia requiring rehospitalization (n  160) 5.2
ata are shown as Nelson-Aalen event rates. Composite outcome indicates death, myocardial inf
TpP  thrombus precursor protein.illip class, use of heparin, and use of beta-blockers), we
ound that patients with TpP greater than the median
ontinued to be at increased risk for death and ischemic
omplications (HR 1.43, 95% CI 1.16 to 1.75, p 
.001) (Table 4). The levels of TpP correlated only
eakly with TnI, hsCRP, and BNP (|r| 0.15 for each).
here was no statistically significant heterogeneity in the
rognostic ability of TpP for the composite outcome in
atients stratified by the presence or absence of elevated
evels of TnI, hsCRP, or BNP (p  NS for all interaction
erms). After adding TnI, hsCRP, and BNP to the
ultivariable model, the relationship between TpP and
ong-term cardiovascular outcomes, as assessed by the
omposite outcome, remained significant (HR 1.51, 95%
I 1.19 to 1.91, p  0.001). Adjusting for baseline
haracteristics, features on presentation, and biomarker
tatus, patients with TpP levels greater than the median
ere also at greater risk of death or MI (HR 1.58, 95%
I 1.09 to 2.30, p  0.02).
iscussion
number of biochemical markers have been shown to
rovide important insights into different aspects of the
athobiology of ACS, and they have been used to assist with
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dial infarction; other abbreviations as in Figure 2.
onths
TpP Quartiles (g/ml)
(n  590) 9–15.9 (n  577) >15.9 (n  586) p Value for Trend
0.3 30.6 31.4 0.0003
2.8 4.5 6.0 0.044
5.5 7.2 7.0 0.222
5.8 9.2 7.1 0.063
7.3 11.9 13.3 0.005
ischemia requiring revascularization, or ischemia requiring rehospitalization.10 M
9–8.9
2
r
c
f
a
t
a
p
h
fi
i
c
(
s
b
A
w
n
F
i
A
a
b
a
l
a
f
i
t
fi
y
p
p
d
t
w
(
fi
g
u
s
s
m
n
q
a
q
c
e
a
c
T
r
s
r
u
a
s
c
HtIoM
T
c
1
2427JACC Vol. 51, No. 25, 2008 Mega et al.
June 24, 2008:2422–9 TpP and Clinical Outcomes in ACSisk stratification following a cardiovascular event. In this
urrent study, we found that a specific marker of fibrin
ormation, TpP, can further help with identifying patients
t increased risk of death or ischemic complications across
he spectrum of ACS, from UA to STEMI. This marker of
ctivated coagulation could potentially provide an additional
athophysiological axis for evaluation of the post-ACS patient.
During the past decade, several markers of coagulation
ave been evaluated in the setting of ACS, including
brinogen, D-dimer, and fibrinopeptide A (3). Fibrinogen,
n particular, has been studied as a predictor of future
ardiovascular events in patients with cardiovascular disease
14–18); yet, as an acute-phase reactant, it can reflect
ystemic inflammation rather than coagulation and throm-
osis (19). D-dimer has also been evaluated in the post-
CS population, and increased levels have been associated
ith recurrent cardiac events (20,21), but the marker has
ot been adopted into clinical practice in this setting.
ibrinopeptide A concentrations have been found to be
ncreased in patients with ACS (3); however, fibrinopeptide
has a half-life of 3 to 4 min in circulation and thereby is
ssociated with fluctuating levels (22,23). In contrast, solu-
le fibrin polymers, such as TpP, serve as particularly
ttractive markers of fibrin formation because they have a
onger plasma half-life (5 to 6 h) and involve the step of the
ctivated coagulation cascade immediately preceding the
OVERALL 2349 1.45 (1.20-1.75)
PRIOR CAD
Yes 1166 1.34 (1.05-1.71)
No 1183 1.46 (1.08-1.98)
INDEX DIAGNOSIS
STEMI 763 1.66 (1.18-2.34)
NSTEMI-UA 1585 1.35 (1.07-1.70)
SX TO RANDOMIZATION
<24 Hours 513 1.28 (0.88-1.87)
24-48 Hours 929 1.20 (0.88-1.63)
>48 Hours 878 1.81 (1.29-2.51)
TX AT RANDOMIZATION
UFH 1448 1.39 (1.10-1.76)
LMWH 314 1.38 (0.82-2.31)
No Heparin 584 1.90 (1.20-3.01)
2 50.5 1HR:
Hazard Ratio (95% CI)
Figure 4 Hazard Ratios for the Composite
Outcome in Subgroups by TpP Level
Hazard ratio plot for the risk of the composite outcome (death, myocardial
infarction, ischemia requiring revascularization, or ischemia requiring rehospi-
talization) with a TpP  median (8.9 g/ml) in specified subgroups. The p
value to test for interaction was 0.18 for all subgroups. CAD  coronary
artery disease; CI  confidence interval; LMWH  low molecular weight hepa-
rin; NSTEMI-UA  non–ST-segment elevation myocardial infarction–unstable
angina; STEMI  ST-segment elevation myocardial infarction; SX  symptoms;
TpP  thrombus precursor protein; TX  treatment; UFH  unfractionated heparin.ormation of fibrin (24). hAfter plaque rupture in the coronary artery, tissue factor
s exposed and activates the coagulation pathway. Pro-
hrombin is converted into thrombin; thrombin then cleaves
brinopeptide A and fibrinopeptide B from fibrinogen,
ielding desAABB fibrin monomer units with newly ex-
osed amino-terminals. These desAABB monomers start to
olymerize via D and E domains creating still-soluble
esAABB fibrin polymers. The specific TpP assay used in
his analysis detects these species of soluble fibrin polymers,
hich serve as the immediate precursors to insoluble fibrin
Fig. 1). When a steady-state concentration is surpassed, the
brin polymers will further polymerize to form an insoluble
el cross-linked by factor XIII (25).
Soluble fibrin polymers, including TpP, have been eval-
ated as diagnostic markers, performing well in some
tudies (24,26,27). The prognostic performance of several
pecies of soluble fibrin in patients with ACS has been
ixed when tested using several different immunologic and
onimmunologic assays (28–31). Early assays provided
ualitative or semiquantitative results with low sensitivity
nd specificity (25). Immunoassays offer more specific,
uantitative assessments of soluble fibrin. We used a mono-
lonal antibody assay specifically targeted at neoepitopes
xposed during the creation of desAABB fibrin polymers,
nd found TpP to be a good predictor of future cardiovas-
ular events across the spectrum of ACS.
In our study, the association between greater levels of
pP and death or ischemic complications was consistent
egardless of the time from symptom onset to biomarker
ampling or index diagnosis. In terms of anticoagulant
eceived during the hospitalization, we found that heparin
se was associated with lower TpP levels, data that are in
ccord with a result from a previous small study, wherein 9
ubjects were found to have significantly lower TpP con-
entrations after a bolus of heparin (32). Additionally,
Rs (95% CIs) Associated with TpP > Median forhe Composite Outcome (Deat , Myocardialnfarction, Ischemia Requiring Revascular zation,r Is hemia Requiring R hospitaliz tion) Afterultivariable Adj tm nt
Table 4
HRs (95% CIs) Associated with TpP > Median for
the Composite Outcome (Death, Myocardial
Infarction, Ischemia Requiring Revascularization,
or Ischemia Requiring Rehospitalization) After
Multivariable Adjustment
Model HR (95% CI) p Value
Unadjusted 1.45 (1.20–1.75) 0.001
Baseline characteristics (adjusted for age, gender,
smoking status, hypertension, dyslipidemia,
body mass index, diabetes, pre-existing
coronary disease, and previous aspirin use)
1.41 (1.16–1.72) 0.001
Baseline characteristics  clinical presentation
(further adjusted for index diagnosis, creatinine
clearance, Killip class, use of heparin, use of
beta-blockers)
1.43 (1.16–1.75) 0.001
Baseline characteristics  clinical presentation 
biomarkers (further adjusted for troponin I,
BNP, hsCRP)
1.51 (1.19–1.91) 0.001
here are 2,349 observations included in the unadjusted model, 2,255 in the model with baseline
haracteristics, 2,167 in the model with baseline characteristics and clinical presentation, and
,754 for the model with baseline characteristics, clinical presentation, and biomarkers.
BNP  B-type natriuretic peptide; CI  confidence interval; HR  hazard ratio; hsCRP 
igh-sensitivity C-reactive protein; TpP  thrombus precursor protein.
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TpP and Clinical Outcomes in ACS June 24, 2008:2422–9eparin use was less common in patients with UA, who
ere found to have greater TpP concentrations. Yet, we
bserved that there was no association between TpP and
chieved PTT in patients on unfractionated heparin, and
he correlation between TpP levels and the duration of
eparin therapy was weak. Importantly, there was no
vidence of heterogeneity in the relationship of TpP and the
se of unfractionated, low molecular weight, or no heparin
hen evaluating outcomes in this study. Moreover, in the
ultivariable model that adjusted for heparin use, TpP
ontinued to be associated with the composite end point.
The results of multivariable modeling also suggested that
pP offered prognostic information independent of other
linical predictors, including traditional cardiovascular risk
actors and index diagnosis, in patients presenting with
CS. After adjusting for baseline characteristics and clinical
eatures on presentation, we found that patients with TpP
evels greater than the median had a 43% increased risk for
eath or ischemic complications. Reflecting its unique
athophysiological axis, TpP levels were only weakly corre-
ated with established biomarkers, including TnI, hsCRP,
nd BNP. Moreover, after further adjusting for these
iomarkers in a multivariable model, the relationship be-
ween TpP and long-term cardiovascular outcomes re-
ained significant.
Elevated levels of TpP in the post-ACS setting, especially
n subjects with later sample acquisition, may reflect en-
anced systemic activation of the coagulation system, be-
ond what occurs with regard to local, intracoronary fibrin
eposition. The concept of the “vulnerable cardiovascular
atient” with thrombogenic blood was highlighted by an
xpert panel report, suggesting that transient alterations in
he coagulation and fibrinolytic system are likely to be
mportant factors contributing to acute cardiac events (33).
easuring markers such as TpP or D-dimer may be one
ay of quantifying an individual’s degree of thrombogenic-
ty during and after an ACS. Such biomarkers hold the
romise of identifying patients who would benefit from a
onger duration or greater intensity of antithrombotic ther-
py. To that end, potent intravenous and oral Xa inhibitors
re under evaluation for both the acute and long-term
reatment of ACS (34–36). Markers of activated coagula-
ion, such as TpP, may someday prove useful in identifying
hich patients would be most likely to derive the greatest
enefit from these potent antithrombotic strategies.
tudy limitations. Several limitations to this analysis
hould be recognized. First, although our analysis suggests
hat the TpP levels assessed during the hospitalization for
CS carry independent prognostic information, the study
as not designed to assess the value of measuring TpP
mmediately at presentation or to compare with other bio-
arkers obtained at this time point. However, within the
ubset of patients who had TpP samples drawn within 24 h
f symptom onset, the relationship between increased TpP
evels and risk of the composite end point was still direc-
ionally consistent.
jSecond, since we measured troponin in these samples,
ore sensitive troponin assays have been developed; deter-
ining the utility of TpP in the context of these assays will
e important. However, troponin and TpP are assessing
ifferent pathobiologic processes, and we found the corre-
ation between the markers to be low in this study. Third,
his analysis was conducted within an orbofiban treatment
rm of the OPUS–TIMI 16 trial, and it is possible that the
tudy medication influenced levels of TpP. However, all
ubjects in this analysis were in the same treatment arm.
dditionally, because the clinical outcomes in this arm did
ot differ significantly from those in the placebo arm, the
esults should be applicable to the broader population of
ost-ACS patients. Nonetheless, as the landscape of anti-
latelet and anticoagulant treatments continues to change,
pP will need to be evaluated in the setting of different
ackground therapies, administered during an ACS event,
nd in long-term follow-up.
Fourth, we performed extensive multivariable adjust-
ents, including baseline characteristics, features on pre-
entation, treatment during the acute hospitalization, and
ther biomarkers; however, we did not have and therefore
ould not adjust for discharge medications. Fifth, TpP
eference ranges in this analysis were generated from healthy
olunteers. The determination of TpP ranges in other
opulations, including hospitalized patients without ACS,
ill be useful. Sixth, in our analysis, we predominantly use
cutpoint based on the median value. Future work will be
eeded to determine the optimal cutpoint based on timing
f sample acquisition. Finally, the value of assessing serial
amples and the comparison of TpP with other markers of
oagulation was not evaluated in this study. Future studies
re needed to address these areas.
onclusions
hrombus precursor protein is used to measure the penulti-
ate product in the formation of fibrin and, in this study,
reater levels of this marker were associated with an increased
isk of death or ischemic complications. After adjustment for
aseline characteristics, features on presentation, and other
iomarkers, a TpP level greater than the median remained a
ignificant predictor of worse cardiovascular outcomes. These
ata suggest that a marker of active coagulation, such as TpP,
an add independent and incremental prognostic information
n patients presenting across the spectrum of ACS and that
pP, in conjunction with other markers of hemostasis, war-
ants additional evaluation in future studies.
eprint requests and correspondence: Dr. Jessica L. Mega,
IMI Study Group, Brigham and Women’s Hospital, 350 Long-
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